WASHINGTON, DC 20549

                                   FORM 12B-25

                           Notification of Late Filing

(Check One):
[ ] Form 10-KSB    [ ] Form 11-K  [ ] Form 20-F  [X] Form 10-QSB  [ ] Form N-SAR
For Period ended: March 31, 2003

[  ] Transition Report on Form 10-K       [  ] Transition Report on Form 10-Q
[  ] Transition Report on Form 20-F       [  ] Transition Report on Form N-SAR
[  ] Transition Report on Form 11-K
For the Transition Period Ended:

Read attached instruction sheet before preparing form. Please print or type.

Nothing in the this form shall be construed to imply that the Commission has
verified any information contained herein

If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:

                                     Part I
                             Registrant Information

Full Name of Registrant:

        NEOGENOMICS, INC.  (F/K/A American Communications Enterprises, Inc.)

Address of principal executive
office (Street and number):     726 Medical Blvd., Suite 101

City, State and Zip Code:       Naples, FL 34110

                                     Part II
                             Rule 12b-25 (b) and (c)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25 (b), the following
should be completed (Check box if appropriate).

         (a) The reasons described in reasonable detail in Part III of this form
         could not be eliminated without unreasonable effort or expense;
         (b) The subject annual report, semi-annual report, transition report on
         Form 10-K, Form 20-F, Form 11-K or Form N-SAR, or portion thereof will
         be filed on or before the 15th calendar day following the prescribed
         due date; or the subject quarterly report or transition report on Form
         10-Q, or portion thereof will be filed on or before the fifth calendar
         day following the prescribed due date; and

         (c) The accountant's statement or other exhibit required by Rule
         12b-25(c) has been attached if applicable.

                                    Part III

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q,
N-SAR or the transition report portion thereof could not be filed within the
prescribed time period. Attach extra sheets if needed.)

The Company has been unable to complete its Form 10-QSB on a timely basis due to
the delay in obtaining financial data and documentation necessary for the
completion of this report. The Company expects to be in a position to file its
Form 10-QSB within the requested 5-day extension period.

                                     Part IV
                                Other Information

(1)  Name and telephone number of person to contact in regard to this
                               Scott Montell, Esq.
                                 (646) 792-2255

(2)  Have all other periodic reports required under Section 13 or 15(d) of the
     Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
     of 1940 during the preceding 12 months or for such shorter period that the
     registrant was required to file such report been filed? If the answer is
     no, identify report(s).
     [  ] Yes  [X] No

     The Company has not yet filed its Annual Report on Form 10-KSB

(3)  Is it anticipated that any significant change in results of operations from
     the corresponding period for the last fiscal year will be reflected by the
     earnings statements to be included in the subject report or portion
     thereof? [ ] Yes [X] No

     If so: attach an explanation of the anticipated change, both narratively
     and quantitatively, and, if appropriate state the reasons why a reasonable
     estimate of the results cannot be made.

NeoGenomics, Inc. (name of registrant as specified in charter) has caused this
notification to be signed on its behalf by the undersigned thereunto duly

Date: May 16, 2003      By:/s/ Michael T. Dent
                               Michael T. Dent, President and Chief Executive